We recently found that purified SORE6+ cells derived from MOLM−13 and MV4−11, two AML cell lines carrying FLT3-ITD, displayed significantly higher CSL phenotype (such as resistance to Ara-C) compared to SORE6− cells [13]. Here, FLT3 is linked to acute myeloid leukemia.